OTC Statins: What We Have Is A Failure To Communicate
This article was originally published in The Tan Sheet
Executive Summary
The immediate prospects for an OTC statin may have been dampened by the lopsided Mevacor panel vote, but persistent enthusiasm among core decision-makers offers optimism in the long term
You may also be interested in...
FDAers Sink Mevacor OTC At Panel Meeting With Unflinching Critique
Two key presentations by FDA reviewers of Mevacor OTC study data may have undermined any chances of J&J/Merck's salvaging a favorable recommendation to switch the drug
Mevacor OTC Panel Rejection Elicits Third Drug Class Talk
A joint FDA panel decision to recommend against approval of over-the-counter Mevacor Daily was tempered by the endorsement of a behind-the-counter drug class by a number of panelists
Pravachol OTC Deal Reached Between Bayer, Bristol
Bayer is following through on its aim to become the preeminent switch player through a deal with Bristol-Myers Squibb for OTC Pravachol in the U.S